On the Representation Theory of an Algebra of Braids and Ties

We consider the algebra ${\cal E}_n(u)$ introduced by F. Aicardi and J. Juyumaya as an abstraction of the Yokonuma-Hecke algebra. We construct a tensor space representation for ${\cal E}_n(u)$ and show that this is faithful. We use it to give a basis for ${\cal E}_n(u)$ and to classify its irreducible representations.Comment: 24 pages. Final version. To appear in Journal of Algebraic Combinatorics

Associative algebraic approach to logarithmic CFT in the bulk: the continuum limit of the gl(1|1) periodic spin chain, Howe duality and the interchiral algebra

We develop in this paper the principles of an associative algebraic approach to bulk logarithmic conformal field theories (LCFTs). We concentrate on the closed $gl(1|1)$ spin-chain and its continuum limit - the $c=-2$ symplectic fermions theory - and rely on two technical companion papers, "Continuum limit and symmetries of the periodic gl(1|1) spin chain" [Nucl. Phys. B 871 (2013) 245-288] and "Bimodule structure in the periodic gl(1|1) spin chain" [Nucl. Phys. B 871 (2013) 289-329]. Our main result is that the algebra of local Hamiltonians, the Jones-Temperley-Lieb algebra JTL_N, goes over in the continuum limit to a bigger algebra than the product of the left and right Virasoro algebras. This algebra, S - which we call interchiral, mixes the left and right moving sectors, and is generated, in the symplectic fermions case, by the additional field $S(z,\bar{z})=S_{ab}\psi^a(z)\bar{\psi}^b(\bar{z})$, with a symmetric form $S_{ab}$ and conformal weights (1,1). We discuss in details how the Hilbert space of the LCFT decomposes onto representations of this algebra, and how this decomposition is related with properties of the finite spin-chain. We show that there is a complete correspondence between algebraic properties of finite periodic spin chains and the continuum limit. An important technical aspect of our analysis involves the fundamental new observation that the action of JTL_N in the $gl(1|1)$ spin chain is in fact isomorphic to an enveloping algebra of a certain Lie algebra, itself a non semi-simple version of $sp(N-2)$. The semi-simple part of JTL_N is represented by $Usp(N-2)$, providing a beautiful example of a classical Howe duality, for which we have a non semi-simple version in the full JTL image represented in the spin-chain. On the continuum side, simple modules over the interchiral algebra S are identified with "fundamental" representations of $sp(\infty)$.Comment: 69 pp., 10 figs, v2: the paper has been substantially modified - new proofs, new refs, new App C with inductive limits construction, et

A transfer-printed micro-LED and polymer-based transceiver for visible light communications

Funding: This work is supported by EPSRC grant EP/K00042X/1. IDWS is a Royal Society Wolfson research merit award holder.Visible light communications (VLC) is an emerging technology that uses LEDs, such as found in lighting fixtures and displays, to transmit data wirelessly. Research has so far focused on LED transmitters and on photoreceivers as separate, discrete components. Combining both types of devices into a single transceiver format will enable bi-directional VLC and offer flexibility for the development of future advanced VLC systems. Here, a proof of concept for an integrated optical transceiver is demonstrated by transfer printing a microsize LED, the transmitter, directly onto a fluorescent optical concentrator edge-coupled to a photodiode, the receiver. This integrated device can simultaneously receive (downlink) and transmit (uplink) data at rates of 416 Mbps and 165 Mbps, respectively. Its capability to operate in optical relay mode at 337 Mbps is experimentally demonstrated.Publisher PDFPeer reviewe

Albuminuria, lung function decline, and risk of incident chronic obstructive pulmonary disease the NHLBI pooled cohorts study

Rationale: Chronic lower respiratory diseases (CLRDs), including chronic obstructive pulmonary disease (COPD) and asthma, are the fourth leading cause of death. Prior studies suggest that albuminuria, a biomarker of endothelial injury, is increased in patients with COPD. Objectives: To test whether albuminuria was associated with lung function decline and incident CLRDs. Methods: Six U.S. population–based cohorts were harmonized and pooled. Participants with prevalent clinical lung disease were excluded. Albuminuria (urine albumin-to-creatinine ratio) was measured in spot samples. Lung function was assessed by spirometry. Incident CLRD-related hospitalizations and deaths were classified via adjudication and/or administrative criteria. Mixed and proportional hazards models were used to test individual-level associations adjusted for age, height, weight, sex, race/ethnicity, education, birth year, cohort, smoking status, pack-years of smoking, renal function, hypertension, diabetes, and medications. Measurements and Main Results: Among 10,961 participants with preserved lung function, mean age at albuminuria measurement was 60 years, 51% were never-smokers, median albuminuria was 5.6 mg/g, and mean FEV 1 decline was 31.5 ml/yr. For each SD increase in log-transformed albuminuria, there was 2.81% greater FEV 1 decline (95% confidence interval [CI], 0.86–4.76%; P = 0.0047), 11.02% greater FEV 1 /FVC decline (95% CI, 4.43–17.62%; P = 0.0011), and 15% increased hazard of incident spirometry-defined moderate-to-severe COPD (95% CI, 2–31%, P = 0.0021). Each SD log-transformed albuminuria increased hazards of incident COPD-related hospitalization/mortality by 26% (95% CI, 18–34%, P, 0.0001) among 14,213 participants followed for events. Asthma events were not significantly associated. Associations persisted in participants without current smoking, diabetes, hypertension, or cardiovascular disease. Conclusions: Albuminuria was associated with greater lung function decline, incident spirometry-defined COPD, and incident COPD-related events in a U.S. population–based sample

Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction

Published online: 11 September 2023Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural integrity, however its role in the heart is unknown. We have demonstrated, using single cell RNA-seq, that fibulin-3 was highly expressed in quiescent murine cardiac fibroblasts, with expression highest prior to injury and late post-infarct (from ~ day-28 to week-8). In humans, fibulin-3 was upregulated in left ventricular tissue and plasma of heart failure patients. Fibulin-3 knockout (Efemp1-/-) and wildtype mice were subjected to experimental myocardial infarction. Fibulin-3 deletion resulted in significantly higher rate of cardiac rupture days 3-6 post-infarct, indicating a weak and poorly formed scar, with severe ventricular remodelling in surviving mice at day-28 post-infarct. Fibulin-3 knockout mice demonstrated less collagen deposition at day-3 post-infarct, with abnormal collagen fibre-alignment. RNA-seq on day-3 infarct tissue revealed upregulation of ECM degradation and inflammatory genes, but downregulation of ECM assembly/structure/organisation genes in fibulin-3 knockout mice. GSEA pathway analysis showed enrichment of inflammatory pathways and a depletion of ECM organisation pathways. Fibulin-3 originates from cardiac fibroblasts, is upregulated in human heart failure, and is necessary for correct ECM organisation/structural integrity of fibrotic tissue to prevent cardiac rupture post-infarct.Lucy A. Murtha, Sean A. Hardy, Nishani S. Mabotuwana, Mark J. Bigland, Taleah Bailey, Kalyan Raguram, Saifei Liu, Doan T. Ngo, Aaron L. Sverdlov, Tamara Tomin, Ruth Birner, Gruenberger, Robert D. Hume, Siiri E. Iismaa, David T. Humphreys, Ralph Patrick, James J. H. Chong, Randall J. Lee, Richard P. Harvey, Robert M. Graham, Peter P. Rainer and Andrew J. Boyl

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p<0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p<0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark